2 cheap high dividend UK stocks I’d buy today

I’ve been investigating two cheap, high-dividend, UK stocks. Here are my reasons why I’d buy these FTSE 100 companies today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are a few things I look out for when analysing UK stocks. The first one is that I don’t want to overpay. The second is an attractive dividend yield. I’m certainly an income-hungry investor.

So I’ve found two dirt-cheap, high-dividend, UK stocks I’d buy right now. These aren’t tech stocks. But I consider them as steady companies that have the potential to continue generating consistent cash flows to pay out income.

#1 – BATS

The first low-price high-dividend UK stock I’d buy is British American Tobacco (LSE: BATS). The shares trade on a price-to-earnings (P/E) ratio of 8x. So I can’t complain about the valuation.

Tobacco may seem like a boring sector (and one that some would shun on ethical grounds), but the company is clearly doing something right. It upgraded its revenue guidance earlier this month. BATS now expects sales growth of more than 5% in its 2021 financial year. This is ahead of the 3-5% range it provided before.

The growth driver is the New Category division. This includes the “reduced risk” vapour products . BATS is backing this business with full force and is encouraging smokers to convert to such alternatives. So far it has been working well and I reckon this could continue.

The shares have a dividend yield of 7.5%, which is covered by earnings approximately 1.5x. Of course, there’s no guarantee this income will continue to be paid out. But the fact that the dividend is supported by earnings, is encouraging for me.

There are risks with the stock. Regulation is one of them. So far the company has managed to weather regulatory headwinds. But with more focus being placed on health and wellness, I reckon regulation will increase. This could put pressure on the BATS share price.

#2 – Aviva

Aviva (LSE: AV) shares are also trading on a dirt-cheap valuation. The stock has a P/E of 8x and a dividend yield of 6.5%. What’s great is that the income is supported by earnings 2x.

I covered the general insurer earlier this month. I commented on how activist investor Cevian Capital has built a 5% stake in the company. In my opinion, this is a good thing because it means that change is likely to be coming.

In my view, the FTSE 100 company had lost its way. But with the arrival of a new CEO, the firm looks as if it’s getting its mojo back. Aviva is now focusing on its core markets and has already made a series of business disposals.

It has already indicated that it’s going to make a capital return to shareholders from the sale proceeds. For me, a board that puts the interest of shareholders at the forefront is always a good thing.

My concern is whether Aviva’s senior management will find the rate of change expected by Cevian and perhaps some other investors a little too much. In my view, an activist investor doesn’t build a stake for no reason. It expects things to move at a fast pace. The two parties seem to be getting along for now, but this could change and impact the share price.

The stock has an attractive dividend yield, which I can’t ignore. Hence I’d buy Aviva shares today.

Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has recommended British American Tobacco. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 for a Stocks and Shares ISA? Here’s how to try and turn it into a monthly passive income of £493

Hundreds of pounds in passive income a month from a £20k Stocks and Shares ISA? Here's how that might work…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£5,000 put into Nvidia stock last Christmas is already worth this much!

A year ago, Nvidia stock was already riding high -- but it's gained value since. Our writer explores why and…

Read more »

Investing Articles

Are Tesco shares easy money heading into 2026?

The supermarket industry is known for low margins and intense competition. But analysts are bullish on Tesco shares – and…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Can this airline stock beat the FTSE 100 again in 2026?

After outperforming the FTSE 100 in 2025, International Consolidated Airlines Group has a promising plan to make its business more…

Read more »

Investing Articles

1 Stocks and Shares ISA mistake that will make me a better investor in 2026

All investors make mistakes. The best ones learn from them. That’s Stephen Wright’s plan to maximise returns from his Stocks…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I asked ChatGPT if £20,000 would work harder in an ISA or SIPP in 2026 and it said…

Investors have two tax-efficient ways to build wealth, either in a Stocks and Shares ISA or SIPP. Harvey Jones asked…

Read more »

Investing Articles

How much would I need invested in an ISA to earn £2,417 a month in passive income?

This writer runs the numbers to see what it takes in an ISA to reach £2,417 a month in passive…

Read more »

Investing Articles

Rolls-Royce shares or Melrose Industries: Which one is better value for 2026?

Rolls-Royce shares surged in 2025, surpassing most expectations. Dr James Fox considers whether it offers better value than peer Melrose.

Read more »